Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Inventory (2016 - 2023)

Lexaria Bioscience's Change in Inventory history spans 9 years, with the latest figure at -$76782.0 for Q2 2023.

  • For Q2 2023, Change in Inventory fell 641.35% year-over-year to -$76782.0; the TTM value through Feb 2024 reached -$76782.0, down 351.14%, while the annual FY2023 figure was -$43069.0, 2076.3% down from the prior year.
  • Change in Inventory for Q2 2023 was -$76782.0 at Lexaria Bioscience, down from $64504.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $80257.0 in Q2 2019 and bottomed at -$88859.0 in Q2 2021.
  • The 5-year median for Change in Inventory is -$5782.0 (2019), against an average of -$6553.4.
  • The largest annual shift saw Change in Inventory crashed 956.66% in 2022 before it surged 1482.92% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $6160.0 in 2019, then dropped by 1.51% to $6067.0 in 2020, then tumbled by 148.03% to -$2914.0 in 2021, then plummeted by 956.66% to -$30791.0 in 2022, then tumbled by 149.37% to -$76782.0 in 2023.
  • Per Business Quant, the three most recent readings for LEXX's Change in Inventory are -$76782.0 (Q2 2023), $64504.0 (Q1 2023), and -$30791.0 (Q4 2022).